Destiny Pharma announces start of a new XF-73 research programme
Aim to test XF-73 as a potential preventive medicine for Oral Mucositis
Oral Mucositis is a common and devastating complication from chemotherapy and radiotherapy suffered by more than 2m cancer patients every year
Brighton, United Kingdom – 05 July 2022 – Destiny Pharma plc (AIM: DEST), a clinical-stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today announces that it has started a new research programme. The research study will be conducted in the US by Oral Mucositis (“OM”) expert Professor Stephen Sonis and will investigate the potential of XF-73 as a preventive medicine to alleviate suffering from OM in patients receiving cancer treatment by testing its efficacy in the gold-standard model of OM.